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In most patients with hypertensive nephropathy and
low glomerular filtration rate (GFR), the kidney function
progressively declines despite the adequate control of the
hypertension with angiotensin-converting enzyme inhibition.
Previously we found that 2 years of oral sodium citrate
slowed GFR decline in patients whose estimated GFR (eGFR)
was very low (mean 33ml/min). This treatment also slowed
GFR decline in an animal model of surgically reduced
nephron mass. Here, we tested if daily oral sodium
bicarbonate slowed GFR decline in patients with
hypertensive nephropathy with reduced but relatively
preserved eGFR (mean 75ml/min) in a 5-year, prospective,
randomized, placebo-controlled, and blinded interventional
study. Patients matched for age, ethnicity, albuminuria, and
eGFR received daily placebo or equimolar sodium chloride or
bicarbonate while maintaining antihypertensive regimens
(including angiotensin-converting enzyme inhibition) aiming
for their recommended blood pressure targets. After 5 years,
the rate of eGFR decline, estimated using plasma cystatin C,
was slower and eGFR was higher in patients given sodium
bicarbonate than in those given placebo or sodium chloride.
Thus, our study shows that in hypertensive nephropathy,
daily sodium bicarbonate is an effective kidney protective
adjunct to blood pressure control along with angiotensin-
converting enzyme inhibition.
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Hypertensive nephropathy is the second leading cause of
complete kidney failure in the United States of America,1 and
most with low glomerular filtration rate (GFR) due to
hypertensive nephropathy have progressive GFR decline
despite blood pressure reduction with regimens including
renin–angiotensin system inhibition.2 Low GFR can be
associated with metabolic acidosis3 and treatment with oral
NaHCO3 slows the decline rate of creatinine (cr) clearance
in subjects with very low cr clearance of various etiologies,4
and with Naþ citrate slows the decline rate of estimated
GFR (eGFR) in those with very low eGFR due to hyper-
tensive nephropathy.5 These data support that metabolic
acidosis contributes to GFR decline in subjects with very
low GFR. Nevertheless, progressive GFR decline occurs
even among hypertensive nephropathy subjects with com-
paratively preserved, chronic kidney disease (CKD) stage 2
eGFR (60–90ml/min).2 The latter subjects are less likely
to have metabolic acidosis by serum acid–base parameters,3
so it is less clear that metabolic acidosis contributed to
GFR decline.
Progressive GFR decline in animals with low GFR due to
reduced nephron mass was slowed by oral alkali, despite
serum acid–base parameters not different from those with
intact nephron mass.6 Similarly, acid-inducing diets led to
endothelin (ET)-mediated GFR decline and oral alkali slowed
GFR decline, better preserved GFR, and lowered kidney ET
production in animals with reduced nephron mass.6,7 Dietary
acid-induced kidney injury in animals with intact nephron
mass8 and with reduced nephron mass7 is mediated by
tubulointerstitial injury through ET receptors.7,8 Tubuloin-
terstitial injury is a component of hypertensive nephropathy9
and its increased severity might predict increased risk for
nephropathy progression.10 We tested the hypothesis that
chronic oral NaHCO3 (1) slows GFR decline rate, (2)
ameliorates urine ET-1 excretion, a surrogate of kidney ET
production, and (3) ameliorates urine excretion of N-acetyl-
b-D-glucosaminidase (NAG), a marker of kidney tubuloin-
terstitial injury.
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RESULTS
Four of the 40 subjects taking NaHCO3 complained of
bloating that resolved when they were instructed to take their
dose four rather than three times daily. None taking NaCl or
placebo voiced complaints. There were no differences in the
spectrum of antihypertensive medications among groups.
Table 1 shows no significant differences in general demo-
graphics and Table 2 shows no significant differences in
eGFR, systolic blood pressure, plasma, and urine parameters
among the three groups.
Figure 1a and b show the estimated trajectories of plasma
values for creatinine (Pcr) and cystatin C (Pcys), respectively,
for the three groups through the 5-year follow-up determined
using linear mixed models (Methods). These estimates are
adjusted for age, sex, race/ethnicity, baseline systolic blood
pressure, and potential renal acid load. The rate of Pcr
(mean±s.e.) change in the NaHCO3 group (0.020±
0.003mg/dl per year) was significantly lower than in the
placebo (0.030±0.003mg/dl per year, P¼ 0.010) and NaCl
(0.032±0.003mg/dl year, P¼ 0.003) groups. There was no
statistical difference in the estimated rate of change of Pcr
between NaCl and placebo groups (P¼ 0.703). Similarly,
the Pcys rate of change in the NaHCO3 group (0.020±
0.003mg/dl per year) was significantly lower than in placebo
(0.035±0.003mg/dl per year, P¼ 0.001), and NaCl (0.030±
0.003mg/dl per year, P¼ 0.027) groups. There was no
statistical difference in the Pcys change rate between NaCl
and placebo groups (P¼ 0.314).
Figure 2a and b show the estimated trajectories of eGFR
calculated using Pcr (crGFR) and Pcys (cysGFR), respectively,
for the three groups through 5 years, using linear mixed
models as above. The crGFR rate of change in the NaHCO3
group (1.47±0.19ml/min per year) was significantly lower
than in the placebo (2.13±0.19ml/min per year, P¼ 0.014)
and NaCl (2.05±0.19ml/min per year, P¼ 0.029) groups.
There was no statistical difference in the crGFR rate of change
Table 1 | General demographics
Placebo NaCl NaHCO3 P-value
n 40 40 40
% Males 48 48 48 0.999
% Black 63 63 63
% Hispanic 25 23 20
% White 13 15 18 0.968
Mean±s.d. Mean±s.d. Mean±s.d.
Age (years) 51.3±8.5 51.5±8.3 51.2±8.2 0.987
Table 2 | Characteristics at study entry (year 0) expressed as
means±s.d.
Placebo
(n=40)
NaCl
(n=40)
NaHCO3
(n=40)
Overall
P-value
Pcr (mg/dl) 0.95±0.08 0.96±0.08 0.96±0.02 0.892
crGFR (ml/min) 75.6±6.2 75.6±6.5 75.3±6.1 0.956
Pcys (mg/l) 1.04±0.09 1.04±0.09 1.05±0.10 0.875
cysGFR (ml/min) 73.5±6.1 73.5±6.5 73.2±6.0 0.969
Systolic BP (mmHg) 155.2±12.9 152.6±14.7 155.3±12.6 0.596
Venous total CO2 (mM) 26.0±0.9 26.4±0.8 26.2±0.7 0.145
PRAL (mEq) 60.4±19.4 59.3±21.1 64.3±17.7 0.477
8 h NAE (mEq) 24.0±5.6 24.8±6.4 24.8±5.6 0.773
Ualb (mg/g creatinine) 422.2±151.6 413.6±147.9 419.3±150.8 0.967
UNAG (U/g creatinine) 2.7±0.7 2.6±0.5 2.7±0.4 0.909
UET (ng/g creatinine) 5.5±1.2 5.7±0.8 5.7±1.0 0.529
Urine Na+ Excretion
(mEq/g creatinine)
73.0±9.5 70.6±10.2 70.9±10.2 0.529
Urine K+ Excretion
(mEq/g creatinine)
39.5±6.6 38.2±6.2 41.1±6.1 0.136
Abbreviations: BP, blood pressure; crGFR, estimated glomerular filtration rate (GFR)
calculated using Pcr; cysGFR, eGFR calculated using Pcys; NAE, net acid excretion;
Pcr, plasma creatinine; Pcys, plasma cystatin C; PRAL, potential renal acid load;
Ualb, urine albumin-to-creatinine ratio; UET, urine endothelin-1-to-creatinine ratio;
UNAG, N-acetyl-b-D-glucosaminidase-to-creatinine ratio.
There were no statistical differences in any parameter among the three groups.
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Figure 1 |Course of plasma values for creatinine and cystatin C.
Trajectories of plasma creatinine (a) and plasma cystatin C (b) in
subjects taking placebo, NaCl, or NaHCO3 for 5 years estimated
using linear mixed models (Methods). *Po0.05 vs placebo;
þPo0.05 vs NaCl.
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Figure 2 |Course of eGFR determined from plasma values of
creatinine and cystatin C. Trajectories of glomerular filtration
rate (GFR) estimated from the plasma creatinine (a) and plasma
cystatin C (b) in subjects taking placebo, NaCl, or NaHCO3 for 5
years estimated using linear mixed models (Methods). *Po0.05 vs
placebo; þPo0.05 vs NaCl.
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between the NaCl and placebo groups (P¼ 0.771). Similarly,
the cysGFR rate of change in the NaHCO3 group
(1.34±0.20ml/min per year) was significantly lower than
in the placebo (2.37±0.20ml/min per year, P¼ 0.0003)
and NaCl (2.19±0.20ml/min per year, P¼ 0.003) groups.
There was no statistical difference in cysGFR change rate
between NaCl and placebo groups (P¼ 0.523).
Table 3 shows the observed values of Pcr and Pcys at
5 years. Pcr was significantly lower in the NaHCO3 group as
compared with both the placebo group and NaCl groups. Pcr
was not significantly different between the NaCl and placebo
groups. Pcys was significantly lower in the NaHCO3 group as
compared with the placebo group, but was not significantly
different as compared with the NaCl group. Similar to Pcr,
Pcys was not significantly different between the NaCl and
placebo groups.
Table 3 also shows crGFR and cysGFR at 5 years for each
group. CrGFR in the NaHCO3 group was statistically
significantly higher as compared with the placebo group,
but was not significantly different compared with the NaCl
group. By contrast, cysGFR was significantly higher in the
NaHCO3 group as compared with both the placebo and the
NaCl groups. CysGFR was not significantly different between
NaCl and placebo groups.
Figure 3 shows estimated trajectories of urine albumin-to-
cr ratio (Ualb) for the three groups using linear mixed
models as above. The Ualb rate of change (mean±s.e.) in the
NaHCO3 group (1.06±3.48mg/g cr per year) was signifi-
cantly lower than the placebo (13.70±3.53mg/g cr per year,
P¼ 0.011) but not the NaCl (9.45±3.50mg/g cr per year,
P¼ 0.09) group. The Ualb rate of change was not
significantly different between the NaCl and placebo groups
(P¼ 0.393).
Figure 4 shows the estimated trajectories of urine
N-acetyl-b-D-glucosaminidase (NAG)-to-cr ratio (UNAG)
for the three groups using linear mixed models as above.
The UNAG rate of change in the NaHCO3 group
(0.035±0.010U/g cr per year) was significantly lower than
both placebo (0.009±0.010U/g cr per year, P¼ 0.002) and
NaCl (0.013±0.010U/g cr per year, P¼ 0.001) groups. The
UNAG rate of change was not significantly different between
Table 3 | Observed 5-year values for the three groups
Placebo NaCl NaHCO3
Overall
P-value
P-value for
NaCl vs Placebo
P-value for
NaHCO3 vs Placebo
P-value for
NaHCO3 vs NaCl
Pcr (mg/dl) 1.12±0.10 1.13±0.08 1.06±0.05 0.001 0.943 0.006 0.002
crGFR (ml/min) 64.0±6.1 65.2±5.5 67.6±4.9 0.020 0.634 0.017 0.146
Pcys (mg/l) 1.23±0.12 1.21±0.11 1.16±0.09 0.017 0.601 0.014 0.141
cysGFR (ml/min) 60.8±6.3 62.7±5.4 66.4±4.9 0.0002 0.317 0.0001 0.014
Systolic BP (mmHg) 133.3±8.1 132.1±6.6 135.1±6.2 0.179 — — —
Venous total CO2 (mM) 26.1±0.8 26.3±0.6 26.4±0.6 0.078 — — —
Ualb (mg/g creatinine) 507.5±228.2 466.5±179.4 387.5±163.1 0.03 0.644 0.026 0.187
UNAG (U/g creatinine) 2.76±0.94 2.74±0.83 2.48±0.46 0.231 — — —
UET (ng/g creatinine) 6.12±1.05 5.87±1.09 4.93±0.81 o0.0001 0.545 o0.0001 0.0003
8 h NAE (mEq) 24.2±5.6 24.9±5.9 19.2±5.4 o0.001 0.859 0.001 0.0001
Urine Na+ Excretion
(mEq/g creatinine)
72.1±7.8 72.2±8.1 76.4±10.2 0.082 — — —
Urine K+ Excretion
(mEq/g creatinine)
39.8±5.8 41.4±5.8 45.1±5.6 0.0005 0.495 0.0005 0.02
Abbreviations: BP, blood pressure; crGFR, estimated glomerular filtration rate (GFR) calculated using Pcr; cysGFR, eGFR calculated using Pcys; NAE, net acid excretion; Pcr,
plasma creatinine; Pcys, plasma cystatin C; PRAL, potential renal acid load; Ualb, urine albumin-to-creatinine ratio; UET, urine endothelin-1-to-creatinine ratio; UNAG, N-acetyl-
b-D-glucosaminidase-to-creatinine ratio.
Values are mean±s.d.
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Figure 3 |Course of urine albumin excretion. Trajectories for
urine albumin-to-creatinine ratio (Ualb) in subjects taking placebo,
NaCl, or NaHCO3 for 5 years estimated using linear mixed models
(Methods). *Po0.05 vs placebo.
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Figure 4 |Course of urine NAG excretion. Trajectories for urine
N-acetyl-b-D-glucosaminidase-to-creatinine ratio (UNAG) in
subjects taking placebo, NaCl, or NaHCO3 for 5 years estimated
using linear mixed models (Methods). *Po0.05 vs placebo;
þPo0.05 vs NaCl.
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the NaCl and placebo groups (P¼ 0.774). Figure 5 shows
estimated trajectories of urine ET-to-cr ratio (UET) for the
three groups. The UET change rate for the NaHCO3 group
(0.08±0.02 ng/g cr per year) was significantly lower than
both the placebo (0.09±0.03 ng/g cr per year, Po0.0001)
and NaCl (0.01±0.03 ng/g cr per year, P¼ 0.010) groups.
The UET rate of change was also significantly lower in the
NaCl group as compared with the placebo group (P¼ 0.026).
Table 3 shows the observed values of Ualb, UNAG, and
UET at 5 years. Ualb at 5 years was significantly lower in the
NaHCO3 group as compared with the placebo group, but was
not significantly different from the NaCl group. Ualb at
5 years was not statistically different between the NaCl and
placebo groups. UNAG at 5 years was not significantly
different between the three groups. UET at 5 years was lower
in the NaHCO3 group as compared with both the placebo
group and the NaCl group. In addition, UET at 5 years was
significantly lower in the NaCl than the placebo group.
Table 3 also shows urine 8-h net acid excretion (8 h NAE)
and urine excretion of Naþ and Kþ at 5 years. Eight hour
NAE at 5 years was statistically significantly lower in the
NaHCO3 group compared with both the placebo and the
NaCl groups, but was not significantly different between
the NaCl group and placebo groups. Urine excretion of Naþ
at 5 years was not significantly different among groups. By
contrast, urine excretion of Kþ at 5 years was significantly
higher in the NaHCO3 group than both the placebo and NaCl
groups. Urine excretion of Kþ at 5 years was not significantly
different between the NaCl and placebo groups.
DISCUSSION
As diets in the industrialized societies are largely acid-
inducing11 and because acid retention in animals with low
GFR induces GFR decline mediated by tubulointerstitial
injury through ET receptors,6,7 we examined if 5 years of oral
NaHCO3 slows eGFR decline rate, ameliorates kidney ET
production, and ameliorates kidney tubulointerstitial injury
in subjects with CKD stage 2 eGFR due to hypertensive
nephropathy. In subjects with early-stage hypertensive
nephropathy whose blood pressure was reduced with regi-
mens including angiotensin enzyme inhibition, 5 years of
NaHCO3 slowed eGFR decline rate, ameliorated kidney ET
production as measured by UET, and ameliorated kidney
tubulointerstitial injury as measured by UNAG. The data
support that 5 years of daily NaHCO3 is an effective adjunct
to blood pressure reduction and renin–angiotensin system
inhibition in slowing progression of early-stage hypertensive
nephropathy.
Earlier studies showed that amelioration of metabolic
acidosis in subjects with very low eGFR (mean
crGFR¼ 33ml/min) due to hypertensive nephropathy with
24 months of Naþ citrate also slowed eGFR decline rate in
subjects whose nephropathy was more advanced than the
present subjects.5 In addition, these earlier studies showed
increasing UET and UNAG in subjects not given alkali but
decreasing levels of each in those given alkali.5 As alkali
therapy is recommended for subjects meeting the criteria of
these earlier studies,12 these earlier studies were not
randomized or blinded.5 In contrast, the present randomized,
placebo-controlled, and blinded studies showed that chronic
oral NaHCO3 also slowed eGFR decline in subjects with
much earlier stage hypertensive nephropathy. Furthermore,
these studies showed increasing UET and UNAG in the
placebo and NaCl groups but decreasing rates for each in
subjects who received NaHCO3. Together, these data support
alkali therapy as an effective kidney-protective adjunct to
blood pressure control and angiotensin converting enzyme
inhibition in the management of both early and more
advanced stages of hypertensive nephropathy. The data also
suggest that the kidney-protective benefit of alkali therapy is
through reducing kidney ET production and tubulointer-
stitial injury, similar to animals with reduced nephron
mass.6,7 The kidney protection provided by alkali therapy
in early-stage nephropathy suggests that such subjects might
ultimately derive greater benefit than those with more
advanced nephropathy by delaying the onset of more
advanced CKD. By slowing GFR decline, NaHCO3 therapy
might reduce the higher cardiovascular risk associated with
lower GFR13 and might also reduce the additional cardio-
vascular risk associated with the faster compared with slower
GFR decline.14 If confirmed by follow-up studies, imple-
mentation of this relatively inexpensive and well-tolerated
therapy in at-risk subjects could yield overall population and
health system benefits by delaying the onset of complete
kidney failure with its devastating effects on individual well-
being and health-care costs.
The mechanism(s) by which chronic NaHCO3 therapy
ameliorated nephropathy progression is unclear but animal
models of reduced GFR provide some insight. Animals with
reduced nephron mass and low GFR have acid retention
compared with those with intact nephron mass, despite no
differences in serum acid–base parameters,6 and acid
retention induces GFR decline mediated by tubulointerstitial
injury through ET receptors.6,7 Although entry and 5-year
serum total carbon dioxide were not different among the
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Figure 5 |Course of urine endothelin excretion. Trajectories for
urine endothelin-1 (ET)-to-creatinine ratio (UET) in estimated
glomerular filtration rate (eGFR) subjects taking placebo, NaCl, or
NaHCO3 estimated using linear mixed models (Methods). *Po0.05
vs placebo; þPo0.05 vs NaCl.
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three groups, 8 h NAE was lower in NaHCO3 subjects,
consistent with alkali ingestion. Whether these subjects with
reduced but relatively preserved GFR have acid retention
compared with those having normal GFR is unknown.
Nevertheless, UET reduction and the lower trajectory of
UNAG, supporting reduced kidney ET production and
reduced tubulointerstitial injury, respectively, are consistent
with animal studies showing that ET and tubulointerstitial
injury contribute to GFR decline.
We used two GFR estimation methods, with their
attendant concerns,15 to follow the course of kidney function.
Regarding the primary outcome (rate of GFR decline), the
statistical analysis showed significantly slower decline in the
NaHCO3 group than both the placebo and NaCl groups with
both GFR estimation methods (crGFR and cysGFR).
Furthermore, the rate of increase in the directly measured
Pcr and Pcys values was slower in the NaHCO3 group than
both the placebo and NaCl groups, which in addition
supports that NaHCO3 slowed GFR decline. Although
statistical comparisons of the 5-year values for these four
parameters (crGFR, cysGFR, Pcr, and Pcys) among NaHCO3,
placebo, and NaCl groups generally supported higher GFR in
the NaHCO3 than the placebo and NaCl groups, not all
comparisons reached the P-value considered to be significant.
Nevertheless, as cysGFR more accurately estimates GFR16 and
more accurately predicts untoward outcomes related to
reduced GFR similar to cardiovascular mortality,17 we
consider that the statistically higher cysGFR in NaHCO3
than placebo and NaCl groups (Table 3) supports better GFR
preservation with 5 years of NaHCO3. Similarly, 2 years of
NaHCO3 better preserved cr clearance in subjects with low
GFR of various causes4 and 2 years of Naþ citrate better
preserved eGFR in hypertensive nephropathy subjects with
much lower eGFR.5 As a slightly higher proportion (18%) of
Whites in the NaHCO3 group compared with the 13 and 15%
in placebo and NaCl groups, respectively, might have
contributed to slower eGFR decline in the NaHCO3 group,
we considered the cysGFR rate of change among Black
subjects only. The results were qualitatively identical to that
described for the entire group of subjects.
There are some additional study limitations. Group
numbers were small although the indicated differences were
highly significant. Consequently, it remains possible, that
greater subject numbers would yield different outcomes. In
addition, we cannot rule out an alkali effect on kidney cr and/
or cystatin C handling. This illustrates the need for a larger
scale study with direct GFR measurements to explore the
efficacy of this potentially effective, adjunctive kidney
protection strategy.
In summary, these studies show that 5 years of oral
NaHCO3 in subjects with reduced but relatively preserved
eGFR due to hypertensive nephropathy slowed the rate of
GFR decline and better preserved GFR, reduced UET, a
surrogate of kidney ET production, and slowed the trajectory
of UNAG, a marker of kidney tubulointerstitial injury. This
inexpensive and well-tolerated therapy appears to be an
effective kidney-protective adjunct to blood pressure reduc-
tion and angiotensin-converting enzyme inhibition in
slowing progression of early-stage hypertensive nephropathy.
MATERIALS AND METHODS
This was a 5-year, prospective, randomized, placebo-controlled,
blinded interventional study of daily oral NaHCO3 versus NaCl and
placebo in subjects with macroalbuminuric hypertensive nephro-
pathy and CKD stage 2 eGFR (60–90ml/min) by MDRD.18 Primary
outcome was reduction in the rate of eGFR decline in the NaHCO3
group compared with the placebo and NaCl groups. After protocol
completion, Pcys was measured19 and cysGFR was calculated using
the CKD–EPI equation19 because cysGFR more accurately estimates
GFR above 60ml/min.16 Secondary outcomes included UET and
two parameters of kidney injury, Ualb, and UNAG. Inclusion criteria
were: (1) non-malignant hypertension; (2) macroalbuminuria (Ualb
4200 but o2000mg/g cr); (3) 60X crGFR o90ml/min (4) X2
clinic visits showing compliance; (5) ageX18 years and able to give
consent. Exclusion criteria were: (1) known primary kidney disease
or findings consistent thereof such as X3 red blood cells per high-
powered field of urine or urine cellular casts; (2) history of diabetes
or fasting blood glucose X110mg/dl; (3) history of malignances,
chronic infections, pregnancy, or clinical evidence of cardiovascular
disease; (4) peripheral edema or diagnoses associated with edema
including heart/liver failure or nephrotic syndrome; (5) smoking or
oral tobacco use within 1 year of recruitment; and (6) history of
medication non-compliance. The diagnosis of hypertensive nephro-
pathy as the exclusive cause for nephropathy was made clinically by
excluding subjects with systemic diseases associated with nephro-
pathy, nephrotic-range proteinuria, and urine abnormalities other
than albuminuria. None had a kidney biopsy. Secondary causes of
hypertension such as renal artery stenosis and hyperaldosteronism
were excluded clinically. Kidney Doppler studies and serum
aldosterone-to-renin ratios were not carried out. Macroalbuminuric
rather than microalbuminuric or normoalbuminuric subjects were
chosen because of their higher risk for GFR decline.20 Smokers were
excluded because smoking enhances GFR decline risk.20 We limited
selection to subjects with a plasma total carbon dioxide of at least
24.5mM, the lower limit of normal for our laboratory, to avoid
subjects with frank metabolic acidosis because metabolic acidosis
contributes to GFR decline in animals with reduced nephron mass.7
We identified 491 subjects in the general clinical population
database whose International Classification of Diseases-9 code listed
hypertension without diabetes, kidney or renal failure/disease,
hematuria, myocardial infarction, stroke, or peripheral vascular
disease, had Ualb X200 but o2000mg/g, crGFR 60X eGFR
o90ml/min, and had at least two primary care physician visits 12
months before recruitment. Clinical notices prompt Ualb for all
hypertensives. After individual record review, 451 still met inclusion
criteria and 419 consented to three consecutive a.m. urines, 1-week
apart, for Ualb to confirm macroalbuminuria and for Pcr to confirm
that crGFR met criteria. Of these, 349 had confirmed macro-
albuminuria without hematuria and crGFR that satisfied criteria.
These 349 subjects were consented then matched according to age
(±2 years), eGFR (±2ml/min), albuminuria (±10%), and
ethnicity (Black, White, Hispanic) into placebo, NaCl, and NaHCO3
groups of 40 subjects each (total of 120 subjects). Within each
triplet, the subject with the lowest identifying number was placebo,
next highest NaCl, and the subject with the highest identifying
number was assigned to NaHCO3. Subjects were followed 5 years
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and all completed at least 2 years of study. Of the 40 in each group,
34 control subjects, 36 NaCl subjects, and 37 NaHCO3 subjects
completed all 5 years.
All groups received identically appearing, scored tablets of
sucrose (placebo), sucroseþNaHCO3, or sucroseþNaCl (Figure 6).
The salt-containing tablets had 10mEq of either NaHCO3 or NaCl
and subjects received 0.5mEq/kg lean body weight daily of NaHCO3
or NaCl for the 5-year study. Each was prescribed tablets to the
nearest one-half tablet according to body weight in kg (for example,
a 70 kg subject received 3.5 tablets daily). Subjects and tablet
dispensers were blinded as to the type of tablet prescribed. We chose
NaHCO3 because of its lower cost and to avoid increased
gastrointestinal aluminum absorption that has been associated with
Naþ citrate.21
Subjects had yearly visits with plasma studies for acid–base
parameters and cr and urine for kidney injury parameters, ET, and
8 h NAE as carried out previously.5 Ualb was used as a general
marker of progressive kidney injury22 and UNAG as a marker of
tubulointerstitial injury.23 UET was measured as a surrogate of
kidney ET production24 because ET mediates nephropathy progres-
sion in animals.7,25,26 Eight-hour NAE was calculated by measuring
urine titratable acidity (TA), ammonium (NH4
þ ), and HCO3
([NH4
þ ]þ [TA][HCO3]). Subjects were instructed to remain
NPO after midnight except for medications before reporting for
8 h NAE where they voided to empty and had venous blood drawn
for pH, PCO2, and total carbon dioxide. At 0800 hours, subjects had
urine collected until 1600 hours and had no intake except 8 ounces
of chilled distilled H2O that was provided every 2 h to promote
urine output. Blood pressure was reduced pharmacologically toward
the recommended levels as previously described.27 Angiotensin-
converting enzyme inhibition comprised the antihypertensive regi-
men of each subject because guidelines recommend angiotensin-
converting enzyme inhibitors for hypertensives with albuminuria.28
We excluded those unable to tolerate angiotensin-converting
enzyme inhibition. Potential renal acid load was measured with a
3-day diary assessment of the type and amount of ingested foods
that were scored as to acid–base content.29
Our local IRB approved the study protocols.
Analytical methods
Plasma/urine cr and urine albumin were measured with the Sigma
Diagnostics Creatinine Kit (Procedure No. 555, Sigma Diagnostics,
St Louis, MO, USA).27 Pcys was measured with a particle-enhanced
immunonephelometric assay (N Latex Cystatin C; Dade Behring,
Somerville, NJ, USA) with a nephelometer (BNII; Dade Behring
Siemens, Deerfield, IL, USA).18 UNAG was measured with a
colorimetric assay (Boehringer Mannheim, Mannheim, Germany).30
UET was measured with a Radio Immuno Assay kit (Peninsula
Laboratories, Belmont, CA, USA) after extraction using Bound Elut
C18 columns (Varian, Harbor City, CA, USA).24 The IRMA SL
Series 2000 blood analysis system (Edison, NJ, USA) measured
venous blood pH and PCO2. Urine and plasma total carbon dioxide
were measured using ultrafluoremetry.31 Urine titratable acidity was
measured by correction to the ambient serum pH by NaOH
addition, NH4
þ by the formalin titrimetric (to ambient serum pH)
method.32 All urine parameters were expressed per g cr of a spot
a.m. specimen.
Statistical methods
We estimated that 108 subjects completing the protocol would yield
80% likelihood to detect a difference in crGFR decline rate among
the three groups at 0.05 significance level assuming decline rates of
2.26ml/min per year in placebo, 1.51ml/min per year in
NaHCO3, and 2.26ml/min per year in the NaCl group. These
expected rates of eGFR decline were based on earlier studies of
subjects with macroalbuminuric hypertensive nephropathy treated
toward recommended blood pressure targets with angiotensin-
converting enzyme inhibitors20 and estimated crGFR decline rate
with oral alkali from unpublished studies of subjects with
hypertensive nephropathy and more advanced CKD.33
Subject demographics were compared among the three treatment
groups by w2-test or one-way analysis of variance, as appropriate.
Baseline, or year 0, values of each parameter were described by the
mean and s.d. and compared among the three groups with one-way
analysis of variance. If the overall P-value was statistically significant,
all pair wise comparisons were performed by Tukey’s post hoc tests.
The 5-year values of each parameter were considered similarly.
We estimated and compared the rates of change in each
parameter between the treatment groups with linear mixed models,
often described as multilevel models. These models are used to
analyze data in situations in which data are correlated within
subjects and in situations where data are incomplete for some
subjects.34 In this study, 13 of the 120 enrolled subjects did not
complete all 5 years. The rate of change per year for the urine
parameters and P-values reported in results are estimated with linear
mixed models. This allows for inclusion of all subjects, not just those
who completed all 5 years, and approximately accounts for the
repeated measures nature of the data. By contrast, in Table 3 we
report the observed mean 5-year values for subjects completing the
5 years protocol. There was no qualitative difference in the statistical
analysis when using the observed or predicted 5-year values. Each
model included terms for the treatment group (placebo, NaCl, or
NaHCO3), year, age, sex (male, female), ethnicity (Black, Hispanic,
or White), entry systolic blood pressure, and potential renal acid
load modeled as fixed effects, and the 120 patients were modeled as
random effects. The error/correlation structure within each subject
was modeled using a general symmetric structure. The general
structure fit significantly better than other error structures
examined, including random intercepts and slopes as well as
autoregressive structures. In view of evidence that ‘practical
120 subjects
eGFR 60–90
40 subjects 40 subjects 40 subjects
Daily
Placebo
Daily
NaCl
Daily
NaHCO3
eGFR
change
rate
Protocol to assess effect of daily NaHCO3
× 5 years on nephropathy progression
Yearly eGFR, serum
and urine studies
Yearly eGFR, serum
and urine studies
eGFR
change
rate
eGFR
change
rate
Figure 6 | Study outline. Outline of protocol to examine the
effect of 5 years of oral NaHCO3, NaCl, or placebo on progression
of hypertensive nephropathy. eGFR, estimated GFR.
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experience based on many longitudinal studies has led to the
empirical observation that variances are rarely constant over time,’ 35
we allowed variance to change over time. As such, available data
from the 120 subjects were included in the mixed model analysis. We
tested for an interaction between treatment group and time with the
likelihood ratio test, and if statistically significant, all pair wise
comparisons were considered. Restricted maximum likelihood
estimation was used to fit the final models. All computations were
performed using the R statistical software system (R Core
Development Team, Vienna, Austria). P-values o0.05 were
considered to be statistically significant.
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